Idioma: Español
Referencias bibliográficas: 22
Paginas: 263-270
Archivo PDF: 242.07 Kb.

FRAGMENTO

Definición

El PFA-100 (del inglés Platelet Function Analizer-100) es una prueba de tamizaje de la función plaquetaria, la cual es simple, no invasiva, reproducible y no requiere de personal especializado para su aplicación. Esta prueba es utilizada para determinar defectos de la hemostasia primaria, a partir de una muestra de sangre total citratada, en pacientes con sospecha de desórdenes trombocitopáticos, trombocitopenia, enfermedad de von Willebrand y en pacientes con tratamiento anti-agregante.

Espectro clínico de aplicación

Las alteraciones de la función plaquetaria o trombocitopatías son defectos funcionales de las plaquetas que pueden ser de origen congénito o adquirido. Algunas de estas alteraciones se especifican en la tabla.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008; 34: 709-733.

2. Campuzano Maya G. PFA-100: una nueva prueba de función plaquetaria sustituta del tiempo de sangría. Medicina & Laboratorio 2013; 19 (11-12): 411- 448.

3. Koscielny J, von Tempelhoff GF, Ziemer S, Radtke H, Schmutzler M, Sinha P, et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10: 155-166.

4. Harrison P, Mumford A. Screening tests of platelet function: update on their appropriate uses for diagnostic testing. Semin Thromb Hemost 2009; 35: 150-157.

5. Acharya S, Barraclough J, Ibrahim MS, Oxby C, Jones SE, Parapia L, et al. The usefulness of the platelet function analyser (PFA-100) in screening for underlying bleeding disorders in women with menorrhagia. J Obstet Gynaecol 2008; 28: 310-314.

6. ACOG Committee on Gynecologic Practice. Committee Opinion: number 263, December 20001. von Willebrand’s disease in gynecologic practice. Obstet Gynecol 2001; 98: 1185-1186.

7. Cariappa R, Wilhite TR, Parvin CA, Luchtman- Jones L. Comparison of PFA-100 and bleeding time testing in pediatric patients with suspected hemorrhagic problems. J Pediatr Hematol Oncol 2003; 25: 474-479.

8. Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb Haemost 2003; 90: 483-490.

9. Kaw D, Malhotra D. Platelet dysfunction and endstage renal disease. Semin Dial 2006; 19: 317-322.

10. van Vliet HH, Kappers-Klunne MC, Leebeek FW, Michiels JJ. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2. Thromb Haemost 2008; 100: 462-468.

11. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-617.

12. Rivera J, Lozano ML, Vicente V. In vitro changes of platelet parameters: lessons from blood banking. Methods Mol Biol 2004; 273: 57-72.

13. Beck KH. Quality control of platelets during storage by the PFA-100: a comparison to platelet aggregation. Transfus Apher Sci 2002; 27: 247-253.

14. Minford AM, Richards EM. Excluding medical and haematological conditions as a cause of bruising in suspected non-accidental injury. Arch Dis Child Educ Pract Ed 2010; 95: 2-8.

15. Siemens Healthcare Diagnostics Inc. Dade ® PFA Cartucho de Prueba Colágeno/EPI y Dade ® PFA Cartucho de Prueba Colágeno/ADP. Illinois, Estados Unidos; 2012.

16. van Werkum JW, Hackeng CM, de Korte FI, Verheugt FW, Ten Berg JM. Point-of-care platelet function testing in patients undergoing PCI: between a rock and a hard place. Neth Heart J 2007; 15: 299-305.

17. Kundu SK, Sio R, Mitu A, Ostgaard RA. Evaluation of platelet function by PFA-100TM. Clin Chem 1994; 40 (9): 1827-1828.

18. Linnemann B, Schwonberg J, Rechner AR, Mani H, Lindhoff-Last E. Assessment of clopidogrel non-response by the PFA-100 system using the new test cartridge INNOVANCE PFA P2Y. Ann Hematol 2010; 89: 597-605.

19. Favaloro EJ, Bonar R. External quality assessment/ proficiency testing and internal quality control for the PFA-100 and PFA-200: an update. Semin Thromb Hemost 2014; 40: 239-253.

20. Lippi G, Fontana R, Avanzini P, Aloe R, Ippolito L, Sandei F, et al. Influence of mechanical trauma of blood and hemolysis on PFA-100 testing. Blood Coagul Fibrinolysis 2012; 23: 82-86.

21. Kottke-Marchant K, Powers JB, Brooks L, Kundu S, Christie DJ. The effect of antiplatelet drugs, heparin, and preanalytical variables on platelet function detected by the platelet function analyzer (PFA-100). Clin Appl Thromb Hemost 1999; 5: 122- 130.

22. Bock M, De Haan J, Beck KH, Gutensohn K, Hertfelder HJ, Karger R, et al. Standardization of the PFA-100(R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999; 106: 898-904.